Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Supernus Pharmaceuticals, Inc. (SUPN) for potential federal securities law violations. This follows the company's announcement that its Phase 2b study of SPN-820 for treatment-resistant depression did not meet its primary endpoint.
February 24, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Supernus Pharmaceuticals faces a legal investigation by Levi & Korsinsky after its Phase 2b study of SPN-820 failed to meet primary endpoints, potentially impacting investor confidence.
The failure of the SPN-820 study is a significant setback for Supernus Pharmaceuticals, as it may affect future revenue prospects and investor confidence. The legal investigation adds further negative sentiment, likely leading to a short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100